Breast Cancer

Oncology / Haematology

A Phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (DS-8201a), an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with T-DM1

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Breast Cancer

Oncology / Haematology

A Randomized, Double-Blind, Phase III Study of embrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4